Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Telemetry devices

This article was originally published in The Gray Sheet

Executive Summary

FDA will begin inspecting manufacturers of wireless telemetry devices after Dec. 8, 2000 to "verify that appropriate action is being taken to assess and mitigate" electromagnetic interference (EMI) risks, according to Office of Compliance guidance released Oct. 20. The guidance recommends that manufacturers utilize the Wireless Medical Telemetry Service created by the Federal Communications Commission to protect against interference, as well as conduct a risk analysis. A guidance on when to submit a new 510(k)s for changes to a telemetry device will be made available

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel